Sushila Rigas
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Year:
2026
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia, and it has been implicated in one in five strokes. While previous studies have suggested that genes expressed in cardiomyocyte subpopulations play a role in AF, our understanding has been limited by the difficulty of isolating these large, fragile cells for single cell analysis. By bringing together large reference datasets from healthy hearts with data from several studies that each isolated small numbers of cardiomyocytes from donors with AF, we can gain new insights into the role of these cells in arrhythmia. Over a million single cells and nuclei were imported into Galaxy from sc/snRNA-seq datasets in public repositories. Together, these studies covered ten regions of the adult human heart as well as the foetal heart, and included samples from donors with AF or Heart Failure. The latest version of the Seurat pipeline was wrapped for Galaxy and used to integrate and cluster this combined dataset, alongside the existing Scanpy tools for comparison. Over 300,000 cardiomyocytes were identified, mainly as single nuclei from the healthy reference datasets. Subclustering of these cardiomyocytes revealed an atrial subpopulation associated with AF, which was then characterised using Galaxy’s Single Cell Omics Lab. Public data has the potential to answer many new questions, particularly in single cell omics, where the original studies often focus on just a subset of the genes or cell types included in the datasets. Galaxy’s public servers enable anyone to run their own analyses on this data with just a laptop and an internet connection, even at the scale of a million cells. Integrating the heart datasets has enabled new comparisons and analyses to be run that wouldn’t have been possible when analysing them separately. The results will contribute to our understanding of AF and help identify new avenues for future research, including potential therapeutic targets.
Year:
2025
Year:
2025
Background EZH2 promotes aggressive-variant prostate cancer (AVPC) progression via histone H3-Lysine-27 tri-methylation (H3K27me3). We hypothesize that epigenetic reprogramming via EZH2 inhibitors (EZH2i) improves the efficacy of chemotherapy in AVPC. Methods We studied the expression of EZH2 in clinical prostate cancer cohorts (bioinformatics). We determined the effect of EZH2i on both cellular- and cell-free-H3K27me3 levels. We measured effects of carboplatin with/without EZH2i on AVPC cell viability (IC 50 ). We studied how EZH2i modulate gene expression (RNA Seq). Results EZH2 was significantly up-regulated in AVPC vs other prostate cancer types. EZH2i reduced both cellular and cell free-H3K27me3 levels. EZH2i significantly reduced carboplatin IC 50 . EZH2i reduced the expression of DNA repair and increased the expression of pro-apoptotic genes. Article Highlights Polycomb-mediated gene silencing promotes prostate cancer progression Aggressive-variant prostate cancers (AVPCs) are characterized by increased activity of the Polycomb-Repressive Complex 2 (PRC2) Here we show that PRC2 inhibitors are scarcely effective as monotherapy in ACPC cells However the combination of PRC2 inhibitors and carboplatin is highly synergistic RNA Seq studies revealed that PRC2 inhibitors enhance carboplatin activity by modulating several key pathways, including DNA repair and apoptosis.
Year:
2024
Collaborators (8)
Benedetto Grimaldi
Senior Researcher
Istituto Italiano di Tecnologia
Shusuke Akamatsu
Professor
Nagoya University Hospital
Xiaoliang Ba
University of Cambridge
Wendi Bacon
Open University
Dan Johnson
Lecturer
Open University
Elena Jachetti
Researcher (non-academic)
Fondazione IRCCS Istituto Nazionale dei Tumori
Francesco Crea
Professor (Chair) of Cancer Pharmacology
Open University
Hilary MacQueen
Professor in Health Sciences
Open University
Make your next move.
Prepare your application
Review drafts before you send them.